All In Biotech

Drug Trial Radar · NCT07084012

A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS

A Phase IIa Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in the Treatment of Acute Ischemic Stroke (AIS)

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 27, 2025

Primary completion

May 31, 2027

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
Collaborators
Beijing Tiantan Hospital
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIa clinical trial with a three-arm design that utilizes randomization, double-blinding, and placebo control. The primary objective of this study is to evaluate the efficacy of single and multiple intravenous infusions of hUC-MSCs injection in patients with AIS. The secondary objective is to assess the safety and tolerability of single and multiple intravenous infusions of hUC-MSCs injection in patients with AIS. The exploratory objective is to investigate the pharmacokinetic and pharmacodynamic characteristics of hUC-MSCs injection in patients with AIS.

Conditions

  • Acute Ischemic Stroke AIS

Interventions

  • hUC-MSCs treatment (high dose)Drug

    2.0×10\^8 cells per infusion, single administration on D0. Infusion of cell medium placebo on Day 7 (±2 days), and Day 14 (±2 days).

  • hUC-MSCs treatment (low dose)Drug

    1.0×10\^8 cells per infusion, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)

  • PlaceboDrug

    Cell medium, 3 administrations, on Day 0, Day 7 (±2 days), and Day 14 (±2 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with an mRS score of 0-2 at different follow-up visits after treatment.Time frame: 360 days
  2. The proportion of subjects with an NIHSS improvement of ≥4 points at different follow-up visits after treatmentTime frame: 90 days
  3. Changes in NIHSS score from baseline at different follow-up visits after treatmentTime frame: 90 days
  4. Trends in the distribution of mRS scores (0-6) at different follow-up visits after treatmentTime frame: 360 days
  5. The proportion of subjects with a Barthel Index (BI) score of ≥95 at different follow-up visits after treatmentTime frame: 360 days
  6. Changes in Fugl-Meyer Motor Function Assessment Scale score from baseline at different follow-up visits after treatmentTime frame: 360 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.